Disease-free survival of women 70 years or older with stage I-II BC treated with BCS and RT
| Autor: | Jedidiah M. Monson, Steven Jeffrey Hager, Mounika Gopi, Beth Kimball |
|---|---|
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 34:e268-e268 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | e268 Background: Breast RT is the standard of care for women undergoing BCS. Recent trends suggest omitting RT for women > 70 years of age. Our retrospective study evaluated the DFS and failure pattern of women > 70 treated with BCS and RT compared with their younger cohorts. Methods: Between 2009-2011, 101 women with Stage I-II BC were treated with BCS and RT at a physician-owned, community-based cancer center. Clinical, pathologic and treatment characteristics were extracted from patients’ medical records. Results: Of the 101 patients, 71 comprised the < 70 cohort and 30 comprised the > 70 cohort. Patients in the older cohort were more likely to have Stage I tumors (80% vs 64%), but the cohorts were otherwise balanced in terms of T-size, grade, ER/PR and Her2 status. RT was typically delivered in a first course of 50.4 Gy to the whole breast followed by a 10 Gy boost. Median DFS for the older cohort was 36 months (range, 1-66) and 41 months for the younger cohort (range, 1-74). There was only one event in the older cohort, a patient who developed DM at 40 months. In the younger cohort one patient developed LR at 54 months, and 4 developed DM at 18, 33, 51 and 54 months. Conclusions: In our community-based study, women > 70 who received BCS and RT experienced excellent DFS and local control. The three-year median DFS observed in the older women in our study suggests that a long-term view should be taken when treating older patients and that biological age rather than chronological age is a better determinant of when cancer therapies should be withheld. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|